Roger Perlmutter 11-4-10

Roger Perlmutter 11-4-10 - 11-4-10 Building Better...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: 11-4-10 Building Better Medicines: Drug Discovery in the 21st CenturyRoger M. PerlmutterI.Business Parta. Innovation Deficit in Pharm?i.The number of new chemical entities produced by the top 50 pharmaceutical companies is too small to sustain the healthy growth of this groupii.New technologies (e.g. genomics, combinational chemistry, etc.) do not appear to have had a major impact on the provision of new drugs in the industryiii.There has been an substantial increase in Research and Development (50 billions/year)1. Although the large amount of money spent is not translating to proportional new drugs and discoveriesiv.Fewer New Drugs are Emerging: Spending more and achieving less1. The revenue from RX is significantly less than the amount of money spent on research and developmentv.View from Investment Bankers: Pharmaceuticals Exit Research and Create Value1. Money should not be spent on R&D, but this is counter-intuitive because without new research there shouldnt be advancements...
View Full Document

This note was uploaded on 09/04/2011 for the course ENGR 102A taught by Professor Staff during the Fall '11 term at UCSB.

Page1 / 2

Roger Perlmutter 11-4-10 - 11-4-10 Building Better...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online